Unity Biotechnology (Unity Biotechnology) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Unity Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Unity Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $22.61 Mil.

Unity Biotechnology Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Unity Biotechnology's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Short-Term Debt & Capital Lease Obligation Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

4.52

7.43

12.58

3.45

Unity Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															13.06	13.70	-	3.45	-

Unity Biotechnology Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Unity Biotechnology Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology (Unity Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

9U90:Germany 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Executives

Anirvan Ghosh	director, officer: Chief Executive Officer	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar	director	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen	officer: See Remarks	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David	director, officer: President	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill	director	215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy	officer: See Remarks	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan	officer: See Remarks	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns	director	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels	director	2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess	officer: Chief Scientific Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005